AD-35 free base

Overview

AD-35 free base is an orally active, blood-brain barrier-permeable acetylcholinesterase inhibitor with an IC 50 of 793 nM. AD-35 free base inhibits metal-induced amyloid-β aggregation and disassembles preformed amyloid-β aggregates. In rat models of cognitive impairment, AD-35 free base attenuates Aβ 25-35 -induced astrocyte activation, TNF-α and IL-1β release, inhibits ERK phosphorylation, and alleviates learning and memory deficits. AD-35 free base can be used for research on Alzheimer's disease.

Application

Products | Products > Disease Areas > Neurological, Eye or Ear Disease | Products > Disease Areas > Neurodegenerative Disease | Products > Disease Areas > Alzheimer's Disease | Products > Signaling Pathways > Neuronal Signaling | Products > Signaling Pathways > Apoptosis | Products > Signaling Pathways > Immunology/Inflammation | Products > Signaling Pathways > Cell Cycle/DNA Damage | Products > Research Areas > Neurological Disease | Products > Signaling Pathways > PERK | Products > Signaling Pathways > Cholinesterase (ChE) | Products > Signaling Pathways > Amyloid-β | Products > Signaling Pathways > TNF Receptor | Products > Signaling Pathways > Interleukin Related

Product Information

• Catalog No.: HY-117710A
• CAS No.: 1531586-58-9
• Molecular Formula: C24H27N3O3
• Molecular Weight: 405.50
• Storage: Please store the product under the recommended conditions in the Certificate of Analysis.

Source

Original product source